Endometrial cancer is the most common female genital cancer that begins in endometrium of the uterus. Signs and symptoms may include vaginal bleeding and pelvic pain. Usually diagnosed by the pelvic examination, ultrasound scanning and other techniques. Treatment may include, chemotherapy, radiation therapy or hormonal therapy. The report gives a comprehensive outlook on endometrial cancer treatment across the globe with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. The report gives historical, current, and future market sizes (US$ Mn) on the basis of treatment, distribution Channel and region. This report studies global endometrial cancer treatment market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, global market report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed global endometrial cancer treatment market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product opportunities). Key stakeholders of the global market report include suppliers, manufacturers, marketers, policymakers, and healthcare service providers engaged in global endometrial cancer treatment products.In September 2019, the US FDA approved Merck’s anti-programmed cell death protein 1 (PD-1) Keytruda and Eisai’s kinase inhibitor Lenvima for certain advanced endometrial carcinoma patients. On May 30, 2019, AbilityPharma (Ability Pharmaceuticals, SL) released the first results of the currently ongoing phase 1/2a clinical trial evaluating ABTL0812 combined with carboplatin and paclitaxel in patients with endometrial cancer or non-small cell lung cancer. The results correspond to the phase 1 part of the Phase 1/2a clinical trial.